Drugs / MDX2301
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07445971 | Mar 2026 → Sep 2027 expected | COVID-19 | ModeX Therapeutics, An OPKO Health Company | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-04-08 | OPKO Health, Inc. | OPKO Health’s ModeX Therapeutics Initiates Clinical Trial of MDX2301 for the Prevention of COVID-19 opko.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MDX2301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07445971 ↗ |
| Route | Intravenous | “MDX2301 as intravenous infusion” NCT07445971 ↗ |